Evogene Ltd. (EVGN) concluded trading on 01/19/23 at a closing price of $0.78, with 0.21 million shares of worth about $0.17 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.05% during that period and on Thursday the price saw a gain of about 4.04%. Currently the company’s common shares owned by public are about 41.22M shares, out of which, 39.74M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the EVGN stock and their offered price forecasts bring an average price target of $4.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $1.00. The stock’s current price level is 80.5% above of average price target set by the analysts, while a rise to estimated low would result in gain of 22.0% for the stock. However, touching the estimated high of $7.00 would mean a gain of 88.86% for the stock.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Tachlit SAL, Tachlit SAL, and Fidelity Nasdaq Composite Index F are the top 3 mutual funds which are holding stakes in Evogene Ltd. Tachlit SAL is currently holding 74128.0 shares of worth totaling $47050.0. The company recently came selling 2688.0 shares which brought its stake up to 0.18% of the company’s outstanding shares. Tachlit SAL sold 6276.0 shares, after which its hold over company’s outstanding shares shrunk to 0.15%, leaving 62909.0 shares with the mutual fund that have a worth of about $39929.0. Fidelity Nasdaq Composite Index F, after buying 59007.0 shares, have now control over 0.14% of the stake in the company. It holds 0.0 shares of worth $37452.0.
However, the stock later moved at a day high price of 0.7860, or with a gain of 4.04%. Stock saw a price change of 6.07% in past 5 days and over the past one month there was a price change of 15.46%. Year-to-date (YTD), EVGN shares are showing a performance of 12.13% which decreased to -47.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.60 but also hit the highest price of $1.62 during that period. The average intraday trading volume for Evogene Ltd. shares is 86.40K. The stock is currently trading 8.40% above its 20-day simple moving average (SMA20), while that difference is up 12.49% for SMA50 and it goes to -10.28% lower than SMA200.
Evogene Ltd. (NASDAQ: EVGN) currently have 41.22M outstanding shares and institutions hold larger chunk of about 4.00% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $33.18M and its 3Y-monthly beta is at 1.04. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 7.30 while making debt-to-equity ratio of 0.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVGN, volatility over the week remained 7.15% while standing at 8.46% over the month.
Analysts are in expectations that Evogene Ltd. (EVGN) stock would likely to be making an EPS of -$0.17 in the current quarter, while forecast for next quarter EPS is -$0.17 and it is -$0.67 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.19 which is -$0.15 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 17.20% while it is estimated to increase by 48.70% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Evogene Ltd. (EVGN)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on October 08, 2021 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Aegis Capital stated Evogene Ltd. (EVGN) stock as a Buy in their note to investors on July 29, 2021, suggesting a price target of $10 for the stock. On December 01, 2020, Cantor Fitzgerald Initiated their recommendations, while on December 16, 2013, Oppenheimer Initiated their ratings for the stock with a price target of $26.
